Prosthetic-valve & native endocarditis
Infective endocarditis (IE) caused by Staphylococcus aureus and Enterococcus faecalis is among the deadliest cardiovascular infections, with in-hospital mortality of 20-30% despite weeks of high-dose intravenous antibiotics and frequent need for valve surgery. These organisms form dense biofilm vegetations on native and prosthetic valves where antibiotic penetration is poor and metabolically dormant "persister" cells survive, driving relapse; methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) further narrow drug options. Lytic bacteriophages are attractive adjuncts because they self-amplify at the infection site, actively penetrate and disrupt biofilm matrix, and kill by a mechanism orthogonal to antibiotics, so resistance to one does not confer resistance to the other. This makes phage-antibiotic combinations a rational salvage strategy for the persistent, biofilm-anchored, drug-resistant bacteremia that defines endocarditis.
How phages act here
Mechanism
Therapeutic phages bind species- and strain-specific surface receptors (e.g., wall teichoic acid on S. aureus; capsular/rhamnose polysaccharides on E. faecalis), so cocktails are matched to the patient's isolate to broaden coverage and pre-empt receptor-mutation escape. Beyond lysing planktonic cells, many anti-staphylococcal and anti-enterococcal phages encode depolymerases and access biofilm-embedded and stationary-phase bacteria that tolerate antibiotics, eroding valve vegetations. Phage-antibiotic synergy (PAS) is repeatedly observed: sub-lethal beta-lactams elongate cells and boost phage replication, and in a vancomycin-resistant E. faecalis prosthetic-valve biofilm model the phage EFLK1 combined with ceftriaxone gave the greatest reduction on pericardial-patch biofilm. Adjacent biologic approaches include purified phage-derived endolysins/lysins (e.g., the anti-staphylococcal lysin exebacase and tonabacase) and engineered/CRISPR-armed phages designed to re-sensitize resistant strains, though for endocarditis the clinical data to date use intravenous whole-phage cocktails alongside standard antibiotics.
Where it stands
Current evidence
As of 2026 the evidence is early but accelerating, and is strongest for S. aureus. The landmark proof of safety was an Australian single-arm trial (Petrovic Fabijan et al., Nature Microbiology 2020) giving the three-phage cocktail AB-SA01 intravenously twice daily for up to 14 days to 13 patients with severe S. aureus infection including bacteremia and endocarditis, with no major adverse events. A widely cited compassionate-use case (Gilbey et al., MJA 2019) used adjunctive IV AB-SA01 for MSSA prosthetic-valve endocarditis on a 30-year-old mechanical aortic valve, producing rapid blood-culture clearance, though the patient later died of embolic complications after declining surgery. The most important new signal is Armata Pharmaceuticals' diSArm Phase 2a randomized, double-blind, placebo-controlled trial (NCT05184764) of IV cocktail AP-SA02 plus best-available antibiotics in complicated S. aureus bacteremia (which includes endocarditis): 42 patients, day-12 clinical response 88% with phage vs 58% with placebo (p=0.047), no relapses in the phage arm, and a favorable safety profile (Miller et al., Open Forum Infect Dis 2026); positive topline results were reported in 2025 and Armata announced FDA End-of-Phase-2 alignment to advance toward Phase 3. For Enterococcus, evidence remains preclinical/in vitro (e.g., the EFLK1 phage + ceftriaxone prosthetic-valve biofilm model) plus scattered compassionate-use reports, with no dedicated endocarditis RCT yet.
Evidence confidence: medium
The data
Key studies & trials
- Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR; Westmead Bacteriophage Therapy Team. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nature Microbiology. 2020;5(3):465-472. ↗
- Gilbey T, Ho J, Cooley LA, Petrovic Fabijan A, Iredell JR. Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus. Medical Journal of Australia. 2019;211(3):142-143.e1. ↗
- Miller LG, Kolar S, Sanders J, et al. A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy in Patients with Complicated Staphylococcus aureus Bacteremia (diSArm). Open Forum Infectious Diseases. 2026;13(Suppl 1):ofaf695.022. ↗
- Hetta HF, Rashed ZI, Ramadan YN, Al-Kadmy IMS, Kassem SM, Ata HS, Nageeb WM. Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis. Biomedicines. 2023;11(10):2860. ↗
Who is working on it
Programs & centers
The possibility
If the diSArm signal holds in Phase 3, IV phage cocktails could become the first new adjunct in decades for the most stubborn S. aureus endocarditis, turning relapse-prone, surgery-bound infections into reliably cleared ones and sparing some patients high-risk valve replacement. Rapid clinical phage microbiology - sequencing a patient's isolate and matching a personalized cocktail within days - points toward precision anti-infective care, while phage-antibiotic synergy may let clinicians resurrect drugs like ceftriaxone or vancomycin against otherwise resistant enterococci. The likely near-term future is not phages replacing antibiotics but a standardized, regulator-approved companion therapy that strips the biofilm armor off valve vegetations so the immune system and conventional drugs can finish the job.